Sedative
PreclinicalSmall molecule
Sedative is one of 54 small molecule programs targeting Sedation. It is currently in Preclinical.
4
Indications
4
Total Trials
2
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
76 competitors in Effectiveness
#DrugCompanyPhaseTrials
1Kesimpta
NovartisPhase 3
Actos
TakedaPhase 3
Mounjaro
Eli LillyPhase 3
Elucirem
GGuerbet
Phase 3
Nicotine Free Cigarettes
PfizerPhase 3
Pneumococcal Conjugate Vaccine
NovartisPhase 3
Botulinum Toxin a
GSKPhase 3
Lidocain
BayerPhase 3
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Welireg
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Effectiveness1 trial
"Comparison of the Effectiveness of Conventional Radiofrequency Thermocoagulation and Chemical Ablation With Phenol on Articular Branches of Femoral and Obturator Nerves in Chronic Hip Pain"
Not yet recruiting·—·N/A·NCT06570746·48 enrolled
Sleep Apnea1 trial
Combination Therapy to Treat Sleep Apnea
Completed·—·N/A·NCT01633827·22 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sedative. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details